|
ABC Liniment, Ayer's Cherry Pectoral, Baza Cream, Combe's Peel, French Mixture, Hoof Rot Formula Equine, Lugol's Solution, Peruna, Vienna Paste�what do these have in common? They are formulas from over the years that occasionally will be the subject of a question from a physician, nurse, patient, etc. Many of these are old, but some are recent. It has been somewhat difficult in the past to track these products down to learn of their composition. Some are named after a person, subject, or even their composition and some have been proprietary in the past.
Now, with the first group (over 1,000) of Named Formulas, the International Journal of Pharmaceutical Compounding (IJPC) will continually add formulas to our database over the next few years so they can be easily accessed. The difficulty with many of these is that they are in old reference books that are out of print and unavailable except in some libraries. There are thousands and thousands of these formulas that IJPC will work on and load onto this site where they can be easily accessed.
Obviously, many of these formulas should not be compounded and are for historical and informational purposes. However, many have utility today and are being used. One will notice that these formulas are "not documented" and are posted for your professional judgment as to whether or not they will be used. If you have a formula that can be included, please send it, and we will try to get it posted. Interestingly, many of these older formulas are still useful and can be compounded!
To access these Named Formulas on www.CompoundingToday.com, after signing in, click on "Formulas" and two options will be available. The first option is the contemporary (Documented Formulas), and the second option will be the Named Formulas (Undocumented Formulas).
Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition
|
|
News
High Costs for Drugs in Japan Signals High Prices for U.S.
The first of a promising new class of cancer drugs went on sale in Japan this week at an average annual cost of $143,000 per patient. Opdivo, from Ono Pharmaceutical Co. and Bristol-Myers Squibb Co., is a PD-1 inhibitor, a new type of drug that works with the body's immune system to fight tumors, including melanoma. Other pharmaceutical companies are also developing PD-1 targeting drugs.
High prices increase the concerns about the affordability of these new drugs. Government health officials, private insurers, and some members of Congress expressed concern that the $84,000-per-patient drug-Sovaldi-from Gilead Sciences Inc. was straining health budgets with some prisons and state Medicaid programs stating that they can't afford to give the drug to every patient who qualified for it medically. Japan prices for patented, brand-name drugs are usually at least 18% lower than in the U.S. Japan imposes price cuts every two years but U.S. manufacturers are free to raise prices in the U.S.
http://online.wsj.com/articles/powerful-new-cancer-drugs-offer-hopeat-
steep-cost-1409788867?cb=logged0.26712899454441924
|
|
Tip of the Week
Recommendations and standards should be "BASED ON SCIENCE," documented, and made available to practitioners! If not documented, it should NOT be enforceable or used unless warranted by extenuating circumstances. How can one require documentation of a professional if the standards to which they are compared are not documented?
|
|
Book Review
FASTtrack: Chemistry of Drugs
Barlow D, Mountford D
July 2014; Paperback; 272 Pages; $36.99
This book has over 300 figures and is a well-illustrated resource on key aspects of organic chemistry, elementary medicinal chemistry, and biochemistry. It is a great review for practitioners and is a great resource for pharmacy students. It has a lot of concise bulleted information, key points, tips, and numerous self-assessment multiple choice questions to aid in the learning and evaluation process.
|
